ClicBio

Executive Summary

ClicBio is a pre-clinical stage biotechnology company headquartered in Cambridge, USA, focused on revolutionizing the treatment of metabolic diseases. Founded in 2021, the company targets the hunger pathway with a novel molecular switch that modulates hypothalamic neurons to regulate appetite. This innovative mechanism has the potential to address a broad range of metabolic disorders, including obesity and diabetes, by directly influencing the brain's control of hunger. While still in early development and having raised no disclosed funding, ClicBio's differentiated approach could offer a new paradigm in metabolic disease therapeutics. The pre-clinical stage means the company faces significant technical and regulatory hurdles, but the specific targeting of hypothalamic neurons may provide a competitive edge over existing therapies. The drug development pipeline is currently unpublicized, and the company's profile completeness is low, indicating limited public information. Nonetheless, the core science holds promise for a large unmet medical need in metabolic health.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round60% success
• Q2 2027Preclinical Proof-of-Concept Data Release50% success
• Q3 2027Research Partnership or Licensing Deal40% success